Nichol Martinuik
Vorsitzender bei ADORBS INC.
Profil
Nichol Martinuik is the founder of Myspray Therapeutics, Inc. which was founded in 2012, where he holds the title of President & Director.
Currently, he is the Chairman, President & Secretary at Adorbs, Inc. where he started in 2023 and is still active.
Aktive Positionen von Nichol Martinuik
| Unternehmen | Position | Beginn |
|---|---|---|
| ADORBS INC. | Vorsitzender | 13.03.2023 |
Myspray Therapeutics, Inc.
 Myspray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Adorbs, Inc., Myspray Therapeutics, Inc. is a Canadian company that develops natural health products for professional results. The company is based in Canora, Canada. Myspray's products are clinically developed, licensed, and manufactured to ensure potency, quality, and safety. The company's flagship product, myshrooms, contains a potency of 40%% polysaccharides from sustainably farmed organic sources and is tested to be pure USP medicinal grade. The company was founded in 2012 by Nichol Martinuik, and Rachel Martinuik has been the CEO of the company since 2012. Myspray Therapeutics was acquired by Adorbs, Inc. on February 10, 2022 for $30.67 million. | Gründer | 01.01.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ADORBS INC. | Consumer Non-Durables |
| Private Unternehmen | 1 |
|---|---|
Myspray Therapeutics, Inc.
Myspray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Adorbs, Inc., Myspray Therapeutics, Inc. is a Canadian company that develops natural health products for professional results. The company is based in Canora, Canada. Myspray's products are clinically developed, licensed, and manufactured to ensure potency, quality, and safety. The company's flagship product, myshrooms, contains a potency of 40%% polysaccharides from sustainably farmed organic sources and is tested to be pure USP medicinal grade. The company was founded in 2012 by Nichol Martinuik, and Rachel Martinuik has been the CEO of the company since 2012. Myspray Therapeutics was acquired by Adorbs, Inc. on February 10, 2022 for $30.67 million. | Commercial Services |
